Our product portfolio includes prescription drugs, medical dermatology and aesthetics, along with therapeutic skin care products aimed at treating skin diseases with a particular focus on acne, rosacea, psoriasis and steroid-responsive dermatoses, skin cancer, and aging skin.
Aklief Product Monograph, Aklief French Product Monograph
Apprilon Product Monograph, Apprilon French Product Monograph
Clobex Spray Product Monograph, Clobex Spray French Product Monograph
Clobex Shampoo Product Monograph, Clobex Shampoo French Product Monograph
Differin/XP Product Monograph, Differin/XP French Product Monograph
MetroGel Product Monograph, MetroGel French Product Monograph
Metvix Product Monograph, Metvix French Product Monograph
Onreltea Product Monograph, Onreltea French Product Monograph
Silkis Product Monograph, Silkis French Product Monograph
TactuPump / TactuPump Forte Product Monograph, TactuPump / TactuPump Forte French Product Monograph
Rosiver Product Monograph, Rosiver French Product Monograph
Benzac Wash 10%
CONSUMER CARE PRODUCTS:
Dysport Aesthetic Product Monograph, Dysport Aesthetic French Product Monograph
MANUFACTURING PLANT – BAIE-D’URFÉ, QC
Since its inauguration in 2000, the Montreal plant has been sharing its passion for dermatology through the manufacturing of products geared towards improving people’s quality of life.
Located in Baie-D’Urfé (on the western tip of the Island of Montreal), the facility is considered to be Galderma’s main manufacturing plant in North America servicing clients worldwide.
At Galderma, our employees and management work side by side to manufacture products that meet the highest standards in the industry. Management values employee initiatives and accountability, all while ensuring a positive working environment.
Recognized as a performing and competitive manufacturing site, our Montreal plant has been growing since its inception. This growth is directly attributed to the quality of our products and the expertise of our professionals. Our employees have crafted our success and we support their professional development.
A SITE IN FULL EXPANSION
In 2013 Galderma finalized phase I of its investment funding plan infusing $53 million to expand its infrastructure and acquire equipment in order to meet the growing demand for its products, thus increasing the capacity of the Montreal plant to 95 million units per year. The company’s business plan between now and 2020 projects 120 million units per year to keep up with international market demand. As such, continuous investments will be made in the years to come.
U.S Food and Drug Administration (FDA)
ISO 14001 environmental management certification
OHSAS 18001 certification for occupational health and safety management
C-TPAT (Customs-Trade Partnership Against Terrorism) concerning the protection of manufactured goods entering the United States from terrorist security threats.
Cetaphil : www.cetaphil.ca
Cetaphil Baby : www.cetaphilbaby.ca
Dysport : https://www.dysportcanada.ca/consumer/
Restylane : https://www.restylane.com/ca/ca-en
Sculpra : http://www.sculptra.ca/
Galderma Connexion : http://galdermaconnexion.ca/user
GALDERMA CANADA INC (HEAD OFFICE)
55 Commerce Valley Drive W, Suite 400, Thornhill, ON, L3T 7V9
905-762-2500 or 1-800-467-2081
CUSTOMER SERVICE INQUIRIES (E.G. ORDERING, PRICING, OPENING AN ACCOUNT, FINDING A SALES REP):
Customer.SERVICE@Galderma.com (Prescription & Consumer products)
Aesthetics.SALES@galderma.com (Aesthetic Injection products)
MEDICAL INFORMATION INQUIRIES (PRODUCT INQUIRIES):
REPORTING ADVERSE EVENTS / SIDE EFFECTS WITH GALDERMA PRODUCT(S):
REPORTING QUALITY ISSUES WITH GALDERMA PRODUCT(S):
GALDERMA PRODUCTION INC. (BAIE-D’URFÉ, QC)
19400 TransCanada Highway,
Baie-D'Urfé (Quebec) H9X 3S4